Clinical Strategies for Developing Next-Generation Cancer Precision Medicines
The clinical development of EGFR inhibitors for non-small cell lung cancer is one of the greatest examples of precision medicine. The three generations of different EGFR inhibitors highlight the growing knowledge and implementation of genetic information into clinical thinking and hypotheses, the testing of these hypotheses in clinical development and, ultimately the acceptance of such targeted therapy as valuable transformational clinical tools. As each generational EGFR-inhibitor therapy is tested in the clinic, the responses of patients together with their individual genomic information provides the stage for the next-generational clinical development of this class of drugs. Non-small cell lung cancer behaves classically like most cancers, and in due time, responding patients will inevitably develop resistance to the targeted therapy. Using a broad range of disease biology, genetic dissection and clever chemistry, the generational clinical development of EGFR inhibitors for non-small cell lung cancer is one of the most inspiring and motivational accounts of how precision medicine is transforming healthcare worldwide.
KeywordsPrecision medicine Lung cancer Mutation screening Personalized medicine Drug target Clinical trials
- Ding PN, Lord SJ, Gebski V, Links M, Bray V, Gralla RJ, Yang JC, Lee CK (2017) Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR-mutated non-small cell lung cancer. J Thorac Oncol 12(4):633–643CrossRefGoogle Scholar
- Fukuoka M, Wu Y-L, Thongprasert S, Sunpaweravong P, Leong S-S, Sriuranpong V et al (2011) Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non–small-cell lung cancer in Asia (IPASS). J Clin Oncol 29:2866–2874CrossRefGoogle Scholar
- Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139CrossRefGoogle Scholar
- Merrick D, Kittelson J, Wintherhalder R, Kotantoulos G, Ingeberg S, Keith RL et al (2006) Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer. Clin Cancer Res 12:2281–2288CrossRefGoogle Scholar
- Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L et al (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306–13311CrossRefGoogle Scholar